

LETTER

Open Access



Early GCase activity is a predictor of long-term cognitive decline in Parkinson's disease

Linn Oftedal¹, Johannes Lange^{1,2}, Kenn Freddy Pedersen^{1,3}, Aleksander Hagen Erga^{1,4}, Ingvild Dalen⁵, Ole-Bjørn Tysnes^{6,7}, Guido Alves^{1,2,3} and Jodi Maple-Grødem^{1,2*} 

Dementia is a serious complication for many patients with advanced Parkinson's disease (PD) and its incidence is increased in PD patients harbouring a mutation in *GBA1* [1]. However, cognitive impairment is not limited to late disease stages and can also manifest in patients with early untreated disease, leading to diminished social function and increased disability and caregiver burden. We have previously shown that reduced activity of the *GBA1* protein product, the lysosomal enzyme glucocerebrosidase (GCase), is linked with long-term progression to PD dementia [2]. In this study, we extend this by determining the association of cerebrospinal fluid (CSF) GCase activity with the development of cognitive impairment through the analysis of neuropsychological test data collected over 10 years of prospective follow-up of patients with incident PD.

A total of 117 patients from the Norwegian ParkWest study [3] with GCase activity measured in CSF samples taken at the time of PD diagnosis (median delay, 38 days) [4] were included in the study (Additional file 1: Table S1). Neuropsychological testing assessed functions in four cognitive domains: attention, executive function, verbal learning and memory, and visuospatial skills. A score for each domain was calculated by taking the average of the test scores after conversion into the Percent of Maximum Possible scores as described in Additional file 2: Methods.

To assess the association of reduced baseline GCase activity with the change in cognitive function over the first 10 years of PD (median follow-up, 9.0 years [interquartile range, 1.0]), we applied linear mixed-effects models. The patients were stratified into tertiles based on the level of CSF GCase activity and those with the highest activity (> 1.12 mU/mg) were compared to the group with medium (0.80–1.12 mU/mg) or low GCase activity (< 0.80 mU/mg). At the time of PD diagnosis, there was no significant difference in the MMSE scores across the three GCase activity groups (Fig. 1a; Additional file 1: Table S2). However, both the medium ($\beta = -1.58$ transformed points; 95% confidence interval [CI] -2.91 to -0.25 , $P = 0.022$) and the low GCase activity groups ($\beta = -2.26$ transformed points; 95%CI -3.59 to -0.94 , $P = 0.001$) were predicted to experience a faster annual decline in MMSE score, compared to the high activity group. Over the 10 years of the study, patients in the high GCase activity group were not predicted to experience a significant decline in MMSE score ($P = 0.159$),

*Correspondence:

Jodi Maple-Grødem

jodi.maple@uis.no; jodi.maple.grodem@sus.no

¹ Centre for Movement Disorders, Centre for Brain Health, Stavanger University Hospital, 4011 Stavanger, Norway

² Department of Chemistry, Bioscience and Environmental Engineering, University of Stavanger, 4021 Stavanger, Norway

³ Department of Neurology, Stavanger University Hospital, 4011 Stavanger, Norway

⁴ Department of Social Studies, University of Stavanger, 4021 Stavanger, Norway

⁵ Section of Biostatistics, Department of Research, Stavanger University Hospital, 4011 Stavanger, Norway

⁶ Department of Clinical Medicine, University of Bergen, 5021 Bergen, Norway

⁷ Department of Neurology, Haukeland University Hospital, 5053 Bergen, Norway



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.




Fig. 1 Prediction of changes of scores measuring cognitive impairment over time. Patients ($n=117$) were grouped by GCCase activity level (high, medium, and low). **a** MMSE scores, and POMP scores for **b** attention, **c** executive function, **d** memory, and **e** visuospatial skills. MMSE scores were transformed before plotting as described in the Methods. *Significant difference from the high GCCase activity group ($P < 0.05$). POMP percent of maximum possible

whereas those in the medium- or low-activity group were estimated to decline from about 29 to 26 or to 24 MMSE points, respectively.

At the baseline visit, there was no significant difference in the performance in tests assessing attention, executive function, verbal learning and memory, or visuospatial skills between the GCCase activity groups (Additional file 1: Table S2). Assessment of the annual change in performance in individual cognitive domains showed that the low activity group was predicted to decline faster in scores of attention ($\beta = -0.92$; 95%CI -1.58 to -0.28 , $P = 0.006$), executive function ($\beta = -0.61$; 95%CI -1.20 to -0.03 , $P = 0.042$), memory ($\beta = -1.60$, 95%CI -2.63 to -0.58 , $P = 0.003$), and visuospatial skills ($\beta = -0.84$ transformed points, 95%CI -1.63 to -0.06 , $P = 0.038$) (Fig. 1b–e; Additional file 1: Table S2). However, the group with the medium level of GCCase activity only declined significantly faster than the high activity group in measures of attention ($\beta = -0.95$; 95%CI -1.60 to -0.30 ; $P = 0.005$), and for the other three cognitive domains studied the difference in the annual rate of change was not significant (all $P > 0.05$). The results were largely unchanged when the analysis was repeated including only the 105 PD patients without *GBAI* mutations (Additional file 2: Methods and Additional file 1: Fig. S1 and Table S2). Specifically, we found that the size of the effect and significance of the association of GCCase activity status with the decline in cognitive function remained comparable apart from the scores for executive function, for which there was no significant difference in the annual decline between the high and the low activity groups ($P = 0.086$).

In the brains of patients with PD, GCCase dysfunction is paralleled by α -synuclein accumulation [5, 6]. The mild negative correlation between α -synuclein pathology and GCCase activity may be involved in the increased cognitive decline observed in the patients with the lowest GCCase activity in this study. However, how GCCase dysfunction influences PD pathology (and vice versa) is unclear. Most *GBAI* mutation carriers do not develop PD [7, 8], suggesting that the relationship is not causative. Recent findings from animal and cell models support that lower GCCase activity levels do not initiate α -synuclein aggregation, but promote α -synuclein aggregation depending on the physiological state of the extant α -synuclein [9, 10], and factors beyond GCCase depletion play a role in influencing the incidence of the disease.

GCCase is a promising target for the treatment of neurodegenerative disorders caused by the progressive aggregation of α -synuclein. A key challenge in developing these therapies is identifying a defined testing window where such interventions would have a maximum impact. At the time of PD diagnosis, the patients in the

three GCCase activity groups had comparable performance and those patients in the low activity group who were cognitively intact could represent a high-risk population to test GCCase-targeting and neuroprotective therapies. Crucially, this could provide a means by which to recruit patients from the idiopathic PD population (i.e., those without a *GBAI* mutation) to pivotal clinical trials that might otherwise prioritise *GBAI*-PD patients.

We have recently shown that the GCCase dysfunction at the time of PD diagnosis is linked to an increased risk of later development of dementia [2]. Although dementia is an important milestone in a clinical setting, it is less suitable as an outcome in clinical trials for modification of cognitive decline as dementia often requires many years of follow-up and/or very large cohorts to capture a meaningful number of events. For trial design, this is compounded as dementia is commonly a late-stage event, and potentially disease-modifying drugs are thought to be most effective when initiated early in the disease course. By contrast, cognitive decline is a gradual process that starts early in a substantial subset of patients and is frequently included as an outcome in PD clinical trials. Therefore, we performed a power calculation to estimate the predicted benefit (concerning trial size) of limiting enrolment to a clinical trial to patients in the lowest tertile of GCCase activity, compared to a design in which all newly diagnosed patients are eligible for trial inclusion (an “all-comer” design) (Additional file 2: Methods). The trial was for a hypothetical therapeutic agent that stopped the decline of total MMSE score. We found that enriching a three-year trial for patients with low GCCase activity reduced the required sample size for the trial by 2.5-fold compared with an equally powered trial without. In one example, a trial designed to have 80% power to observe the primary outcome would necessitate the recruitment of 658 “all-comers” with early PD, whereas only 266 low-GCCase-activity participants would be needed for the same power (Additional file 1: Fig. S2).

Our study had some limitations. We did not account for anxiety or depression, which can affect performance in cognitive test batteries and have been linked to *GBAI* in other populations. Further, we did not account for other pathological changes such as co-morbid Alzheimer’s disease and neuroinflammation, which are reported risk factors for cognitive impairment in PD [11]. Our study had also several strengths, including the recruitment of incident, unselected patients that are representative of the PD population of the region, the analysis of CSF samples collected at the time of initial clinical diagnosis, the long follow-up time with repeated batteries of the same neuropsychological tests, and low attrition rates.

In conclusion, we found that low CSF GCCase activity at the time of initial diagnosis is linked to a faster annual

decline in clinical scales measuring global cognition and specific cognitive domains over the first 10 years of PD. The link between GCCase dysfunction and disease progression provides insight into the pathogenesis of the disease and novel perspectives for GCCase-targeted therapies to prevent neurodegeneration, and could provide a valuable biomarker to identify patients at risk of more severe disease.

Abbreviations

CI	Confidence interval
GCCase	Glucocerebrosidase
MMSE	Minimal-Mental State Examinations
PD	Parkinson's disease

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s40035-023-00373-x>.

Additional file 1: Table S1. Cohort overview and GCCase activity at baseline. **Table S2.** Relationship between GCCase activity status and predicted annual change in scores in tests measuring cognitive function estimated using linear mixed models. **Fig. S1.** Prediction of scores measuring cognitive impairment over time. **Fig. S2.** Reduced trial size in GCCase-targeted clinical trials compared to a traditional "all-comer" design.

Additional file 2: Methods.

Acknowledgements

We are grateful to the participants of our study for their contributions and all the members of the Norwegian ParkWest study group and other personnel involved in the study.

Author contributions

LO performed the enzymatic activity assays and was a major contributor in writing the manuscript. JL designed the study, prepared the samples, and was a major contributor in writing the manuscript. KFP, O-BT and GA played a major role in the collection, preparation and interpretation of clinical data. AHE contributed to the design of the study and was a major contributor in writing the manuscript. ID performed the statistical analyses. JMG designed the study, performed the statistical analyses, and prepared the first draft of the manuscript. All authors read and approved the final manuscript.

Funding

This work was supported by the Research Council of Norway (287842), the Norwegian Parkinson's Research Foundation, and the Norwegian Health Association (16152). The Norwegian ParkWest study has received funding from the Research Council of Norway (177966), the Western Norway Regional Health Authority (911218), the Norwegian Parkinson's Research Foundation, and Rebergs Legacy. LO, JMG and GA are supported by the Research Council of Norway (287842). JMG and JL are supported by the Norwegian Health Association (16152).

Availability of data and materials

The datasets used during the current study are not publicly available due to the condition of the study's ethical approvals but are available from the corresponding author on reasonable request.

Declarations

Ethics approval and consent to participate

The study was approved by the Western Norway Regional Committee for Medical and Health Research Ethics and all subjects signed written informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Received: 9 March 2023 Accepted: 27 July 2023

Published online: 28 August 2023

References

- Liu G, Peng J, Liao Z, Locascio JJ, Corvol JC, Zhu F, et al. Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson's disease. *Nat Genet.* 2021;53(6):787–93.
- Oftedal L, Maple-Grodem J, Dalen I, Tysnes OB, Pedersen KF, Alves G, et al. Association of CSF glucocerebrosidase activity with the risk of incident dementia in patients with Parkinson disease. *Neurology.* 2023;100(4):e388–95.
- Alves G, Muller B, Herlofson K, HogenEsch I, Telstad W, Aarsland D, et al. Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study. *J Neurol Neurosurg Psychiatry.* 2009;80(8):851–7.
- Oftedal L, Maple-Grodem J, Forland MGG, Alves G, Lange J. Validation and assessment of preanalytical factors of a fluorometric in vitro assay for glucocerebrosidase activity in human cerebrospinal fluid. *Sci Rep.* 2020;10(1):22098.
- Murphy KE, Gysbers AM, Abbott SK, Tayebi N, Kim WS, Sidransky E, et al. Reduced glucocerebrosidase is associated with increased alpha-synuclein in sporadic Parkinson's disease. *Brain.* 2014;137(Pt 3):834–48.
- Munoz SS, Petersen D, Marlet FR, Kucukkose E, Galvagnion C. The interplay between Glucocerebrosidase, alpha-synuclein and lipids in human models of Parkinson's disease. *Biophys Chem.* 2021;273:106534.
- Alcalay RN, Dinur T, Quinn T, Sakanaka K, Levy O, Waters C, et al. Comparison of Parkinson risk in Ashkenazi Jewish patients with Gaucher disease and GBA heterozygotes. *JAMA Neurol.* 2014;71(6):752–7.
- Anheim M, Elbaz A, Lesage S, Durr A, Condroyer C, Viallet F, et al. Penetrance of Parkinson disease in glucocerebrosidase gene mutation carriers. *Neurology.* 2012;78(6):417–20.
- Henderson MX, Sedor S, McGeary I, Cornblath EJ, Peng C, Riddle DM, et al. Glucocerebrosidase activity modulates neuronal susceptibility to pathological alpha-synuclein insult. *Neuron.* 2020;105(5):822–36.
- Fredriksen K, Aivazidis S, Sharma K, Burbidge KJ, Pitcairn C, Zunke F, et al. Pathological alpha-syn aggregation is mediated by glycosphingolipid chain length and the physiological state of alpha-syn in vivo. *Proc Natl Acad Sci U S A.* 2021;118(50):e2108489118.
- Ryman SG, Yutsis M, Tian L, Henderson VW, Montine TJ, Salmon DP, et al. Cognition at each stage of Lewy body disease with co-occurring Alzheimer's disease pathology. *J Alzheimers Dis.* 2021;80(3):1243–56.

Ready to submit your research? Choose BMC and benefit from:

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.

Learn more biomedcentral.com/submissions

